Prediction of response to recombinant human erythropoietin in the anemia of cancerBeguin, Yves ; in Nowrousian, M. R. (Ed.) Recombinant human erythropoietin (rhEPO) in clinical oncology (2nd Ed.) (2008) Detailed reference viewed: 11 (1 ULg) rhEPO in hematopoietic stem cell transplantation; Beguin, Yves ![]() in Nowrousian, M. R. (Ed.) Recombinant human erythropoietin (rhEPO) in clinical oncology (2nd Ed.) (2008) Detailed reference viewed: 11 (3 ULg) Comment je traite...La leucémie myéloblastique aiguë (LMA) du sujet age en bon état général.Lejeune, Marie ; Beguin, Yves ; De Prijck, Bernard et alin Revue Médicale de Liège (2008), 63(2), 59-63 This article describes the treatment of acute myeloid leukemia in older patients with good performance status, and then discusses briefly some future therapeutic perspectives. Detailed reference viewed: 153 (6 ULg) Cord blood transplantation in a child with Pearson's disease.; Dresse, Marie-Françoise ; Robinet, Sébastien et alin Pediatric Blood & Cancer (2008), 51(4), 566 Detailed reference viewed: 36 (4 ULg) Iron deficiencyBeguin, Yves ; in Gasche, C. (Ed.) Anemia in inflammatory bowel disease (2008) Detailed reference viewed: 8 (2 ULg) ErythropoiesisBeguin, Yves ![]() in Gasche, C. (Ed.) Anemia in inflammatory bowel disease (2008) Detailed reference viewed: 13 (5 ULg) Le sang de cordon ombilicalBeguin, Yves ![]() in Revue du Praticien (La) (2008), 58 Detailed reference viewed: 22 (4 ULg) The hematopoiesis-supporting activity of mesenchymal stem cells increases with the number of passagesBriquet, Alexandra ; Beguin, Yves ; Gothot, André ![]() in Experimental Hematology (2007, September), 35(9, Suppl. 2), 125-125 Detailed reference viewed: 23 (11 ULg) Study of contribution of signalling pathways Notch, Wnt, Shh and BMP in mesenchymal stem cell prohaematopoietic activityBriquet, Alexandra ; ; et alin Acta Clinica Belgica (2007, August), 62(4), 256 Detailed reference viewed: 10 (1 ULg) Mature erythrocyte parameters as new markers of functional iron deficiency in haemodialysis: sensitivity and specificityBovy, Christophe ; Gothot, André ; Krzesinski, Jean-Marie et alin Nephrology Dialysis Transplantation (2007), 11 Background. The percentage of hypochromic red blood cells (RBCs) (%HYPO) has been demonstrated as the best predictor of response to iron loading in haemodialysis patients treated with recombinant human ... [more ▼] Background. The percentage of hypochromic red blood cells (RBCs) (%HYPO) has been demonstrated as the best predictor of response to iron loading in haemodialysis patients treated with recombinant human erythropoietin (rHuEPO). However, we have previously shown that this parameter is positively influenced by erythropoietic activity since reticulocytes are considered hypochromic by cell counters. New cell counters are able to determine cell volume and haemoglobin (Hb) concentration separately on reticulocytes and mature erythrocytes. The aim of this study was to assess the sensitivity and specificity of mature erythrocyte parameters in detecting functional iron deficiency (FID). Methods. A total of 32 stable chronic haemodialysis patients in the maintenance phase of rHuEPO therapy were included. Classical parameters of iron monitoring and mature erythrocyte parameters were measured after a 4-week iron-free period. Patients were classified as responders (R) or non-responders (NR) to an iron load of 100 mg iron sucrose at each dialysis session for 4 weeks, according to whether their Hb increased by >1 g/dl at the end of iron loading. Results. Twelve patients were identified as responders. Receiver operating characteristic (ROC) curve analysis demonstrated %HYPO and its corresponding parameter on mature erythrocyte, %HYPOm, as the best predictors of FID. The other parameters were ordered as follows: tranferrin saturation (TSAT), ferritin (FRT), mature RBC Hb content (CHm), mean corpuscular Hb concentration (MCHC), percentage of mature erythrocytes with a low CHm (%lowCHm), mean content in Hb (MCH) and reticulocyte Hb content CHr. Comparing the parameters at different cut-offs, the best sensitivity, specificity and efficiency were demonstrated for HYPOm>6%. Conclusion. The best efficiency to predict FID was found for %HYPOm>6%. The predictive value of %HYPO was quite similar. The clinical impact of %HYPOm in iron monitoring should also be tested in the induction phase of rHuEPO treatment because of its independence from erythropoietic activity. [less ▲] Detailed reference viewed: 53 (6 ULg) Haematopoietic stem cell transplantation for children in BelgiumDresse, Marie-Françoise ; Beguin, Yves ![]() in Tijdschrift van de Belgische Kinderarts = Journal du Pédiatre Belge (2007), 1 Detailed reference viewed: 25 (5 ULg) Limited usefulness of CA125 measurement in the management of Hodgkin's and non-Hodgkin's lymphoma.Bonnet, Christophe ; Beguin, Yves ; Fassotte, Marie-France et alin European Journal of Haematology (2007), 78(5), 399-404 BACKGROUND: Several papers have reported an association of high CA125 serum levels with advanced non-Hodgkin's lymphoma (NHL) as well as a relationship between high CA125 values and poor outcome. PATIENTS ... [more ▼] BACKGROUND: Several papers have reported an association of high CA125 serum levels with advanced non-Hodgkin's lymphoma (NHL) as well as a relationship between high CA125 values and poor outcome. PATIENTS AND METHODS: Ninety-nine patients with NHL or Hodgkin's disease (HD) underwent serum CA125 assessment at diagnosis. Gender, age, presence of B symptoms, performance status (PS), histology, sites of tumor involvement, presence of effusion, clinical stage, age-adjusted International Prognostic Index, C-reactive protein (CRP), Hb, lactate deshydrogenase (LDH) and beta2-microglobulin were evaluated for their association with serum CA125 levels. The impact of CA125 levels and other features on overall (OS) and progression-free (PFS) survival was also assessed. RESULTS: CA125 serum levels were elevated in 34% of the patients, including 19% of patients with aggressive NHL, 45% of patients with indolent NHL, and 29% of patients with HD. Univariate analyses showed that CA125 levels correlated with poor PS, the presence of B symptoms, advanced clinical stage, abdominal, bone marrow or mediastinal involvement, presence of effusions, high aaIPI, low Hb levels and high CRP, LDH or beta2-microglobulin levels. In multivariate analysis, bone marrow involvement, the presence of effusions, and high aaIPI were all associated with high CA125 serum levels. In univariate analyses, OS and PFS were affected by age (PFS only), poor PS, B symptoms, advanced clinical stage, bone marrow or abdominal involvement (PFS only), high aaIPI, low Hb, high CRP or beta2-microglobulin levels. OS and PFS were not different in patients with normal or elevated CA125 levels. Multivariate analyses showed significantly inferior OS and PFS in patients with high beta2-microglobulin but no influence of CA125. CONCLUSION: While CA125 serum level correlates significantly with a number of features associated with more aggressive disease, it does not enhance the performance of standard prognostic markers in the management of patients with NHL or HD. [less ▲] Detailed reference viewed: 62 (3 ULg) Actualités thérapeutiques en hématologie.De Prijck, Bernard ; Baron, Frédéric ; Beguin, Yves et alin Revue Médicale de Liège (2007), 62(5-6), 384-90 This article focuses on recent advances in four important areas of hematology: aggressive lymphomas, allogeneic hematopoietic stem cell transplantation, multiple myeloma, and molecular therapy of cancer. Detailed reference viewed: 83 (8 ULg) Evaluation clinique de la fonction du thymus.Castermans, Emilie ; Morrhaye, Gabriel ; et alin Revue Médicale de Liège (2007), 62(11), 675-8 The essential role of the thymus is to install an extremely diverse repertoire of T lymphocytes that are self-tolerant and competent against non-self, as well as to generate self-antigen specific ... [more ▼] The essential role of the thymus is to install an extremely diverse repertoire of T lymphocytes that are self-tolerant and competent against non-self, as well as to generate self-antigen specific regulatory T cells (Treg) able to inactivate in periphery self-reactive T cells having escaped the thymic censorship. Although indirect, techniques of medical imaging and phenotyping of peripheral T cells may help in the investigation of thymic function. Nowadays however, thymopoiesis is better evaluated through quantification by PCR of T-cell receptor excision circles (TREC) generated by intrathymic random recombination of the gene segments coding for the variable parts of the T-cell receptor for antigen (TCR). The TREC methodology is very valuable in the circumstances not associated with intense proliferation or apoptosis of peripheral T lymphocytes. [less ▲] Detailed reference viewed: 76 (12 ULg) Evaluation de la thymopoiese: applications cliniques.Castermans, Emilie ; Morrhaye, Gabriel ; et alin Revue Médicale de Liège (2007), 62(12), 725-9 In the precedent article, we have described how T-cell generation in the thymus (thymopoiesis) may be currently evaluated through quantification by PCR of T-cell receptor excision circles (TREC) generated ... [more ▼] In the precedent article, we have described how T-cell generation in the thymus (thymopoiesis) may be currently evaluated through quantification by PCR of T-cell receptor excision circles (TREC) generated by intrathymic random recombination of the gene segments coding for variable parts of T-cell receptor for antigen (TCR). In hematology, TREC methodology helps in a better understanding of immune reconstitution after graft of hematopoietic stem cells: first there is a proliferation of mature T cells present in the graft, then a differentiation of naive T cells. In geriatrics, the homeostasis of the peripheral T-cell repertoire is maintained through proliferation of peripheral memory T cells rather than through thymic generation of naive T cells. In addition, TREC quantification constitutes a novel major tool for deciphering the tight control of thymopoiesis by the neuroendocrine system. [less ▲] Detailed reference viewed: 52 (11 ULg) FDG-PET for the routine follow-up in NHL: First prospective evaluationJerusalem, Guy ; ; Beguin, Yves et alin Journal of Clinical Oncology (2006, June 20), 24(18, Part 1 Suppl. S), 439 Detailed reference viewed: 24 (6 ULg) Despite inhibition of hematopoietic progenitor cell growth in vitro, the tyrosine kinase inhibitor imatinib does not impair engraftment of human CD133+ cells into NOD/SCIDbeta2mNull mice.Pirson, Laurence ; Baron, Frédéric ; Meuris, Nathalie et alin Stem Cells (2006), 24(7), 1814-21 There is potential interest for combining allogeneic hematopoietic cell transplantation (HCT), and particularly allogeneic HCT with a nonmyeloablative regimen, to the tyrosine kinase inhibitor imatinib ... [more ▼] There is potential interest for combining allogeneic hematopoietic cell transplantation (HCT), and particularly allogeneic HCT with a nonmyeloablative regimen, to the tyrosine kinase inhibitor imatinib (Glivec; Novartis, Basel, Switzerland, http://www.novartis.com) in order to maximize anti-leukemic activity against Philadelphia chromosome-positive leukemias. However, because imatinib inhibits c-kit, the stem cell factor receptor, it could interfere with bone marrow engraftment. In this study, we examined the impact of imatinib on normal progenitor cell function. Imatinib decreased the colony-forming capacity of mobilized peripheral blood human CD133(+) cells but not that of long-term culture-initiating cells. Imatinib also decreased the proliferation of cytokine-stimulated CD133(+) cells but did not induce apoptosis of these cells. Expression of very late antigen (VLA)-4, VLA-5, and CXCR4 of CD133(+) cells was not modified by imatinib, but imatinib decreased the ability of CD133(+) cells to migrate. Finally, imatinib did not decrease engraftment of CD133(+) cells into irradiated nonobese diabetic/severe combined immunodeficient/beta2m(null) mice conditioned with 3 or 1 Gy total body irradiation. In summary, our results suggest that, despite inhibition of hematopoietic progenitor cell growth in vitro, imatinib does not interfere with hematopoietic stem cell engraftment. [less ▲] Detailed reference viewed: 60 (30 ULg) The place of positron emission tomography imaging in the management of patients with malignant lymphoma.Jerusalem, Guy ; Beguin, Yves ![]() in Haematologica (2006), 91(4), 442-4 Detailed reference viewed: 10 (4 ULg) Recombinant human erythropoietin therapy after allogeneic hematopoietic cell transplantation with a nonmyeloablative conditioning regimen: low donor chimerism predicts for poor response.; Baron, Frédéric ; Willems, Evelyne et alin Experimental hematology (2006), 34(7), 841-50 PURPOSE: After allogeneic hematopoietic stem cell transplantation with nonmyeloablative conditioning (NMHCT), many patients experience prolonged anemia and require red blood cell (RBC) transfusions. We ... [more ▼] PURPOSE: After allogeneic hematopoietic stem cell transplantation with nonmyeloablative conditioning (NMHCT), many patients experience prolonged anemia and require red blood cell (RBC) transfusions. We enrolled 60 consecutive patients undergoing NMHCT in a phase II trial to determine the optimal utilization of recombinant human erythropoietin (rHuEPO) therapy in this setting. PATIENTS AND METHODS: The first 14 NMHCT recipients did not receive rHuEPO (control group). Nineteen patients were scheduled to start rHuEPO on day 0 (EPO group 2) and 27 patients on day 28 after the transplant (EPO group 1). RHuEPO was administered subcutaneously once weekly at a dose of 500 U/kg/wk with the aim of achieving hemoglobin (Hb) levels of 13 g/dL. The 3 groups were well balanced for major characteristics. RESULTS: During the first month (p < 0.0001) as well as days 30 to 100 (p < 0.0001) and days 100 to 180 (p < 0.0001), Hb values were higher in patients receiving rHuEPO compared to those not receiving it. However, transfusion requirements were significantly decreased only in the first month in EPO group 2 (p = 0.0169). T-cell chimerism above 60% on day 42 was the best predictor of Hb response (p < 0.0001) or Hb correction (p = 0.0217), but myeloid chimerism above 90% also predicted for Hb response (p = 0.0069). Hb response was also decreased in patients receiving CD8-depleted grafts and increased in the few patients not receiving TBI, but only in univariate analysis. CONCLUSIONS: Anemia after NMHCT is sensitive to rHuEPO therapy, but less so than after conventional allogeneic HCT. RHuEPO decreases transfusion requirements only in the first 30 days posttransplant. T-cell chimerism below 60% on day 42 impaired Hb response, suggesting possible inhibition of donor erythropoiesis by residual recipient lymphocytes. A prospective randomized trial should be performed with rHuEPO starting on the day of transplantation to assess its clinical benefit in terms of transfusion requirements and quality of life. [less ▲] Detailed reference viewed: 46 (3 ULg) |
||